Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Hospital Policy / Regulatory

China Elevates Pediatric Healthcare Infrastructure – NHC Expands National Children’s Medical Center Network to 14 Facilities

Fineline Cube May 7, 2026
Company Drug

Sino Biopharmaceutical’s Subsidiary Tianqing Secures Expanded NMPA Approval for Saitanxin – First-in-Class CDK2/4/6 Inhibitor Moves to First-Line Breast Cancer

Fineline Cube May 7, 2026
Company Drug

Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio

Fineline Cube May 7, 2026
Company Deals

Simcere Pharmaceuticals Licenses Idorsia’s Insomnia Therapy Daridorexant for Greater China

Fineline Cube Nov 16, 2022

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the establishment of a licensing agreement with...

Company

Sirnaomics Announces Key Executive Promotions Effective November 15

Fineline Cube Nov 16, 2022

Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) has announced key changes to its C-suite,...

Company Drug

Hengrui Pharmceuticals’ SHR0302 Achieves Positive Results in Phase III Atopic Dermatitis Study

Fineline Cube Nov 16, 2022

China-based Jiangsu Hengrui Pharmceuticals (SHA: 600276) has announced positive results from the randomized, double-blind, placebo-controlled,...

Company Drug

Kanghong Pharma Gains NMPA Approval for Innovative Eye Injection KH631

Fineline Cube Nov 16, 2022

China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced receiving clinical trial approvals...

Company Drug

Antengene’s ATG-008 Shows Promising Results in Cervical Cancer and Hepatocellular Carcinoma Studies

Fineline Cube Nov 16, 2022

Shanghai-based biopharma Antengene Corp., Ltd (HKG: 6996) has announced positive preliminary results from the TORCH-2...

Company Drug

CStone Pharmaceuticals Launches AML Public Welfare Project with China Social Welfare Foundation

Fineline Cube Nov 16, 2022

The acute myeloid leukemia (AML) public welfare project, initiated by the China Social Welfare Foundation...

Company Drug

Betta Pharmaceuticals’ BPI-D0316 Accepted for NMPA Review for NSCLC Adjuvant Therapy

Fineline Cube Nov 16, 2022

China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced that its clinical trial filing for...

Company Drug

Kelun-Biotech’s SKB264 Receives FDA Approval for Phase II Study

Fineline Cube Nov 16, 2022

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd has announced receiving approval from the US FDA to...

Company Deals

Junovabio Secures Pre-Series A Funding for Tumor Molecular Diagnosis

Fineline Cube Nov 16, 2022

Junovabio, a Shanghai-based molecular diagnostics specialist, has reportedly raised “tens of millions” of renminbi in...

Company Deals

Lupeng Pharma Raises USD 35 Million in Pre-Series B Financing Round

Fineline Cube Nov 16, 2022

China-based Lupeng Pharmaceutical Ltd has reportedly raised USD 35 million in Phase 2 of a...

Company Drug

Peru Approves BMS’s Reblozyl and BeiGene’s Brukinsa

Fineline Cube Nov 15, 2022

Peru’s General Directorate of Medicines, Supplies and Drugs (DIGEMID) has approved Bristol-Myers Squibb’s (BMS; NYSE:...

Company Deals

Silk Round Fund and INA Invest in Indonesian Pharma Companies

Fineline Cube Nov 15, 2022

The Chinese state-owned Silk Round Fund (SRF) and Indonesia’s sovereign fund INA have reportedly agreed...

Company Drug

LaNova Medicines Gets NMPA Approval for LM-305 Clinical Study

Fineline Cube Nov 15, 2022

Shanghai-based cancer therapy developer LaNova Medicines Ltd has announced that it has received approval from...

Company Drug

Everest Medicines’ Nefecon NDA Accepted for IgA Nephropathy in China

Fineline Cube Nov 15, 2022

China-based biotech Everest Medicines (HKG: 1952) announced that the National Medical Products Administration (NMPA) has...

Company

CStone Pharmaceuticals Suspends Suzhou Plant Operations to Cut Costs

Fineline Cube Nov 15, 2022

CStone Pharmaceuticals (HKG: 2616) has officially responded to recent news reports regarding the suspension of...

Company Medical Device

Hotgen Receives NMPA Approval for HBV RNA Assay Kit

Fineline Cube Nov 15, 2022

China-based Hotgen Biotech Co., Ltd (SHA: 688068) has announced that it has received marketing approval...

Company Drug

Innovent Biologics Initiates Phase III Trial for Mazdutide in Obesity

Fineline Cube Nov 15, 2022

China-based Innovent Biologics, Inc. (HKG: 1801) has announced the first patient dosing in the randomized,...

Company Drug

Guangdong Zhongsheng Starts Phase III Trial for COVID-19 Drug RAY1216

Fineline Cube Nov 15, 2022

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced the enrollment of the first...

Company Drug

Yabao Receives FDA Clearance for Generic Nexavar

Fineline Cube Nov 15, 2022

China-based Yabao Pharmaceutical Group Co., Ltd (SHA: 600351) has announced that it has received Abbreviated...

Company Deals

Hansoh Pharmaceutical Licenses Biotheus’ Bispecific Antibody PM1080 for Greater China

Fineline Cube Nov 15, 2022

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced a licensing agreement with fellow...

Posts pagination

1 … 595 596 597 … 661

Recent updates

  • Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist
  • GSK Reports Solid Q1 2026 Results – Specialty Medicines and Shingrix Drive Growth as Company Maintains Strong 2031 Outlook
  • Novo Nordisk Reports Record Q1 2026 Results – Wegovy Pill Achieves Strongest-Ever GLP-1 Launch as Total Sales Surge 32%
  • Eli Lilly Commits Additional $4.5 Billion to Indiana Manufacturing – Genetic Medicine Facility Launches as Total Investment Exceeds $21 Billion
  • China Elevates Pediatric Healthcare Infrastructure – NHC Expands National Children’s Medical Center Network to 14 Facilities
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Company

GSK Reports Solid Q1 2026 Results – Specialty Medicines and Shingrix Drive Growth as Company Maintains Strong 2031 Outlook

Company

Novo Nordisk Reports Record Q1 2026 Results – Wegovy Pill Achieves Strongest-Ever GLP-1 Launch as Total Sales Surge 32%

Company

Eli Lilly Commits Additional $4.5 Billion to Indiana Manufacturing – Genetic Medicine Facility Launches as Total Investment Exceeds $21 Billion

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.